Last reviewed · How we verify
NCT03674203
Efficacy of Platelet-rich Plasma in Treatment of Melasma
Phase 2 trial testing Platelet-Rich Plasma in Melasma in 20 participants. Completed in 31 July 2018.
31 May 2018
Quick facts
| Lead sponsor | Instituto Mexicano del Seguro Social |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 May 2017 |
| Primary completion | 31 May 2018 |
| Estimated completion | 31 July 2018 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- Platelet-Rich Plasma
Conditions studied
- Melasma — all drugs for Melasma →
Sponsor
Instituto Mexicano del Seguro Social — full company profile →
Who can join
18 and older, female only, with Melasma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The application of Platelet Rich Plasma (PRP) on three occasions with an interval of 15 days between each one, is related to a decrease in the intensity of the spots and improvement in the quality of the skin of patients with melasma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03674203
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Platelet-Rich Plasma
Trials testing the same drug.
- NCT07184307 — Platelet-Rich Plasma Versus Botulinum Toxin for Refractory Overactive Bladder: A Randomized Trial · NA · recruiting
- NCT06535425 — Participants With Knee Osteoarthrosis · NA · completed
- NCT04640662 — The Effects of Platelet-Rich Plasma Versus Prolotherapy On Rotator Cuff Tendinopathy: A Randomized Controlled Trial. · Phase 1 · completed
- NCT04659447 — Clinical Study of Platelet-rich Plasma Promoting Tendon-bone Healing in Anterior Cruciate Ligament Reconstruction · Phase 1 · unknown
- NCT03548662 — The Effect of Platelet Rich Plasma Injection Combined With Exercise Rehabilitation in Patients With Rotator Cuff Tear · Phase 1 · completed
Other recruiting trials for Melasma
Currently open trials in the same condition.
- NCT06845540 — Oral Metformin for Treating Melasma in Latin American Women · Phase 1, PHASE2 · recruiting
- NCT06644157 — Treatment and Prevention of Melasma Relapses by Using 1064nm 650 Microsecond Laser · NA · active not recruiting
- NCT07034560 — Effectiveness of Oral Melatonin vs Oral Tranexamic Acid in the Treatment and Recurrence of Melasma · Phase 4 · active not recruiting
- NCT06516419 — Development of Products Based on Secretom From Stem Cell Conditioned Medium for Melasma Therapy · NA · recruiting
- NCT05942248 — The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis · NA · recruiting
Other Instituto Mexicano del Seguro Social trials
Trials by the same sponsor.
- NCT07536009 — "Effectiveness of a Telerehabilitation Program Versus a Conventional Rehabilitation Program in Patients With Subacromial · NA · not yet recruiting
- NCT06632184 — Peritoneal Lavage Using Saline or Saline With Ondansetron for Pain Control After Laparoscopic Cholecystectomy · Phase 4 · active not recruiting
- NCT07073846 — Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery. · Phase 4 · recruiting
- NCT07406971 — Safety of Transmucosal Capsaicin Sphenopalatine Ganglion Stimulation in Acute Ischemic Stroke · Phase 2 · recruiting
- NCT07134504 — Primary Prostatic Lymphoma on a 66 Year-old Male in Mexico. · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03674203 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Instituto Mexicano del Seguro Social
- Last refreshed: 28 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03674203.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing